Search ARM

TRACT Therapeutics, Inc., a startup biotechnology company, is developing TregCel, a personalized product consisting of the patient’s own naturally occurring regulatory T cells expanded ex vivo in clinically quantities and infused back to the patient to regulate immune response. This therapeutic treatment has been shown in previous studies to eliminate organ transplant rejection and re-establish balance to the immune system of a patient suffering from an autoimmune disease by transferring the patient to a state of remission.

Contact TRACT Therapeutics
Visit Website